X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NOVARTIS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NOVARTIS TORRENT PHARMA/
NOVARTIS
 
P/E (TTM) x 28.5 360.4 7.9% View Chart
P/BV x 5.4 17.7 30.5% View Chart
Dividend Yield % 1.0 1.6 61.8%  

Financials

 TORRENT PHARMA   NOVARTIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
NOVARTIS
Mar-16
TORRENT PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,768982 180.0%   
Low Rs1,186556 213.2%   
Sales per share (Unadj.) Rs346.1252.9 136.8%  
Earnings per share (Unadj.) Rs55.262.1 88.8%  
Cash flow per share (Unadj.) Rs73.363.3 115.8%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.3 72.9%  
Book value per share (Unadj.) Rs257.1363.6 70.7%  
Shares outstanding (eoy) m169.2231.96 529.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.0 140.3%   
Avg P/E ratio x26.812.4 216.3%  
P/CF ratio (eoy) x20.112.2 165.8%  
Price / Book Value ratio x5.72.1 271.6%  
Dividend payout %25.416.1 157.7%   
Avg Mkt Cap Rs m249,88724,580 1,016.6%   
No. of employees `00011.80.8 1,566.6%   
Total wages/salary Rs m9,9341,801 551.5%   
Avg. sales/employee Rs Th4,971.510,748.9 46.3%   
Avg. wages/employee Rs Th843.22,395.2 35.2%   
Avg. net profit/employee Rs Th792.42,641.1 30.0%   
INCOME DATA
Net Sales Rs m58,5698,083 724.6%  
Other income Rs m2,233829 269.2%   
Total revenues Rs m60,8028,913 682.2%   
Gross profit Rs m13,773234 5,880.7%  
Depreciation Rs m3,06937 8,362.9%   
Interest Rs m2,0562 114,200.0%   
Profit before tax Rs m10,8811,025 1,061.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,545752 205.5%   
Profit after tax Rs m9,3361,986 470.1%  
Gross profit margin %23.52.9 811.6%  
Effective tax rate %14.273.4 19.4%   
Net profit margin %15.924.6 64.9%  
BALANCE SHEET DATA
Current assets Rs m53,84112,678 424.7%   
Current liabilities Rs m31,6122,433 1,299.3%   
Net working cap to sales %38.0126.7 29.9%  
Current ratio x1.75.2 32.7%  
Inventory Days Days9733 297.2%  
Debtors Days Days8422 372.5%  
Net fixed assets Rs m42,07969 60,808.2%   
Share capital Rs m846160 529.5%   
"Free" reserves Rs m42,65511,460 372.2%   
Net worth Rs m43,50111,621 374.3%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25014,400 703.1%  
Interest coverage x6.3570.5 1.1%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.6 103.0%   
Return on assets %11.313.8 81.5%  
Return on equity %21.517.1 125.6%  
Return on capital %19.623.6 83.3%  
Exports to sales %00.7 0.0%   
Imports to sales %018.6 0.0%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs mNA1,503 0.0%   
Fx inflow Rs m20,066186 10,771.0%   
Fx outflow Rs m5,3041,821 291.3%   
Net fx Rs m14,762-1,635 -903.2%   
CASH FLOW
From Operations Rs m10,1272,531 400.1%  
From Investments Rs m-7,869-8,270 95.2%  
From Financial Activity Rs m-1,918-386 497.3%  
Net Cashflow Rs m212-6,125 -3.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 2.0 351.0%  
FIIs % 12.6 1.6 787.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.5 40.9%  
Shareholders   26,511 41,647 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STERLING BIOTECH  PFIZER  DR. DATSONS LABS  ORCHID PHARMA LTD  SANOFI INDIA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS